Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (15531)	2/20/1998 4:38:00 PM
From: celeryroot.com	Respond to of 32384

Off topic There are only FIVE more trading days to take advantage of this wonderful offer from CYGS. You can be first in line for their cancer cure while you sit on the beach in Costa Rica eating shrimp from their shrimp farm. CYGS touts itself as a competitor to GERN. To: broke2 (117 ) From: KGoodson Monday, Jan 5 1998 6:43PM EST Reply # of 167 From BBNS, Kerry Hot Off the Wire Date: Mon, 5 Jan 1998 18:36:50 -0500 To: grizz <grizz@the-link.net> Reply-To: naclip@www.newsalert.com Subject: News Story Cryogenic Solutions Inc. Licenses TeloVector Technology to Costa Rican Clinic Business Wire - January 05, 1998 18:27 %CRYOGENIC-SOLUTIONS CYGS %TEXAS %BIOTECHNOLOGY %MEDICINE V%BW P%BW HOUSTON--(BUSINESS WIRE)--Jan. 5, 1998-- Mike Skillern, newly appointed president of Cryogenic Solutions Inc. (OTC BB:CYGS), announced that CSI has agreed to license its TeloVector(TM) technology to Clinica Lirpa, S.A. of Costa Rica. Clinica Lirpa, S.A. is especially interested in the gerontology (anti-aging) and oncology (anti-cancer) applications of the TeloVector. The license agreement will permit Clinica Lirpa, Ltd. to utilize the company's ssDNA vector technology for research, trial, and commercial purposes in Costa Rica. Clinica Lirpa will be responsible for all regulatory compliance and approval in Costa Rica as a term of the agreement. As a condition of the license agreement, Clinica Lirpa, has agreed to "preferential access" for anyone owning 5,000 or more shares of CSI common stock as of March 1, 1998. "Essentially, Clinica Lirpa will confirm reservations to qualified individuals with at least 5,000 shares registered in their name," said Skillern. "Everyone else will be served on a space available basis. This preferential access will be for all services offered by Clinica Lirpa, not just services developed from our TeloVector(TM)." In April 1997, the company acquired technology and began perfecting the patent for their TeloVector(TM) which can synthesize single strands of DNA (ssDNA) inside cells to repair telomere ends shortened during cell division (mitosis). "Hopefully, history will show 1997 as a groundwork year, and 1998 as our breakthrough year for real progress," said chairman Dell Gibson. "We are planning a series of announcements throughout the first quarter of 1998 now that our telomeric ssDNA vector cassette is ready for cell studies." Clinica Lirpa spokesman, Jorge Castro Olmos expressed full confidence in the potential of the TeloVector(TM) technology. "We are pleased to be the first medical facility that will offer the therapies the ssDNA vector will provide, and we're looking forward to demonstrating the full range of possibilities." CONTACT: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399 email: cygs@wt.net website: biogenix.com